Peter HansenI have previously written about Arcturus (NASDAQ:ARCT). This is one of my preferred biotech startup plays. The company is close to the commercial launch of the Kostaive self-amplifying mRNA COVID-19 vaccine. Meiji, their partners in Japan, is responsible for the regulatory application so that the vaccine complies with the regulatory demands for the 2024-2025 flu season in Japan. The phase 3 data have revealed a strong immune response, validating the STARR Platform for self-amplifying mRNA va ...